sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: MM (Multiple Myeloom)

Trial: HOVON 36 MM


News
1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


No news


1. Overview



Summary

A study of the efficacy, morbidity and quality of life of the standard treatment with Melphalan and Prednison versus an intensified treatment in elderly patients with Multiple Myeloma: A Phase III study.


Status

closed



Study details



Target number of patients

230


Date of activation

11-Nov-1997


Date closed

11-Nov-1999


Approved by

CKVO 97-02


Change history / amendement

HOVON 36 was closed due to high toxicity-levels, namely in the intensive arm of treatment, especially Cycle 1. It was unlikely that the aims of the study - reduced toxicity, faster response and improvement of the quality of life - would be realized. HOVON 36 had 72 registered patients.


2. Patient eligibility criteria



Inclusion criteria

Patients with multiple myeloma not yet treated with chemotherapy.
Age > 64
WHO performance status 0, 1, 2 or 3.
Salmon and Durie stages Ib, IIa, IIb, IIIa and IIIb.
A well-measurable tumor parameter.


Exclusion criteria

Severe cardiac, pulmonary or hepatic disease.
Dependency on kidney function replacement therapy.
Previously treated with cytostatics and/or alpha-interferon.
A history of second primary malignant disease other than stage I carcinoma of the cervix and non-melanomatic cancer of the skin.


3. Registration (& randomization) of patients



Registration

Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...: http://www.hdc.hovon.nl/top


Registration criteria

The following information will be requested:



Name of the caller
Name of the hospital
Pysician in charge of the patient�s treatment
Protocol number
Patient's initials
Hospital registration number
Date of birth
Sex
Stage (Salmon and Durie)
Previous treatment of MM with chemotherapy or IFN-alfa
Presence of a measurable tumor parameter
Informed consent
WHO performance status
Presence/absence of severe cardiac, pulmonary or liver disease
Dependency on kidney function replacement therapy
Presence of other primary malignancies
Does the patinet agree to participate in research on the quality of life?
If so, name and address of the patient


4. Participating parties



Principal investigator

PW Wijermans (hematley@worldonline.nl)


Coordinating investigator(s)

ECM van Pampus


Statistician(s)

W.L.J. van Putten (w.vanputten@erasmusmc.nl)


Central data management

A Meurisse (meurisse@stah.azr.nl)


Other functions

Statisticians:
J Hermans
Morbidity and Quality of Life Investigators:
CA Uyl-de Groot
I Buijt (E-mail Address: buijt@econ.bmg.eur.nl)

Please contact monitors at hdcmonitorteam@erasmusmc.nl


5. Participating sites



Site
Included patients *
NL-Amersfoort-Meander MC
5
NL-Amsterdam-AMC
2
NL-Amsterdam-Bovenij Ziekenhuis
2
NL-Amsterdam-OLVG
7
NL-Amsterdam-Sint Lucas Andreas ZH, Lucas
2
NL-Amsterdam-Slotervaart Ziekenhuis
3
NL-Amsterdam-VUMC
0
NL-Breda-Amphia ziekenhuis, locatie Langendijk
5
NL-Delfzijl-Delfzicht ziekenhuis
1
NL-Den Bosch-Jeroen Bosch ziekenhuis
2
Show 39 more...
* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.

6. Instruction videos



7. Download documentation / forms




return to top